ArticlePloS one2011
MicroRNA expression signatures of bladder cancer revealed by deep sequencing.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
154 citing papers in PubMed, 283 citations in OpenAlex.
- Evaluation of urinary miRNA-96 as a potential biomarker for bladder cancer diagnosis.Medical oncology (Northwood, London, England) · 2015Trial
- hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.Discover oncology · 2025Article
- Clinical relevance of circulating biomarkers in breast cancer metastasis detection: "insights from liquid biopsy technology".Research in pharmaceutical sciences · 2025Article
- Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer.International journal of molecular sciences · 2025Article
- Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and Potential Therapeutic Implications.International journal of molecular sciences · 2025Review
- Profiles of urinal exosomal miRNAs derived from bladder cancer.Central European journal of urology · 2024Article
- Clinical value of microRNA-19a-3p and microRNA-99a-5p in bladder cancer.Archives of medical science : AMS · 2023Article
- Review
- EVs-miRNA: The New Molecular Markers for Chronic Respiratory Diseases.Life (Basel, Switzerland) · 2022Review
- Article
- circRNA CRIM1 regulates the migration and invasion of bladder cancer by targeting miR182/Foxo3a axis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Article
- MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.Scientific reports · 2022Article
- Global analysis of miRNA-mRNA regulation pair in bladder cancer.World journal of surgical oncology · 2022Article
- The miRNome of canine invasive urothelial carcinoma.Frontiers in veterinary science · 2022Article
- Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 and Its Related Molecules as Potential Biomarkers in Small-Cell Lung Cancer.BioMed research international · 2022Article
- Biomarkers in the Light of the Etiopathology of IC/BPS.Diagnostics (Basel, Switzerland) · 2021Review
- MicroRNA-490-3p and -490-5p in carcinogenesis: Separate or the same goal?Oncology letters · 2021Review
- A novel diagnostic signature based on three circulating exosomal mircoRNAs for chronic obstructive pulmonary disease.Experimental and therapeutic medicine · 2021Article
- Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer.Journal of ovarian research · 2021Article
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundMicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression. They are aberrantly expressed in many types of cancers. In this study, we determined the genome-wide miRNA profiles in bladder urothelial carcinoma by deep sequencing. METHODOLOGY/PRINCIPAL
findingsWe detected 656 differentially expressed known human miRNAs and miRNA antisense sequences (miRNA*s) in nine bladder urothelial carcinoma patients by deep sequencing. Many miRNAs and miRNA*s were significantly upregulated or downregulated in bladder urothelial carcinoma compared to matched histologically normal urothelium. hsa-miR-96 was the most significantly upregulated miRNA and hsa-miR-490-5p was the most significantly downregulated one. Upregulated miRNAs were more common than downregulated ones. The hsa-miR-183, hsa-miR-200b ∼ 429, hsa-miR-200c ∼ 141 and hsa-miR-17 ∼ 92 clusters were significantly upregulated. The hsa-miR-143 ∼ 145 cluster was significantly downregulated. hsa-miR-182, hsa-miR-183, hsa-miR-200a, hsa-miR-143 and hsa-miR-195 were evaluated by Real-Time qPCR in a total of fifty-one bladder urothelial carcinoma patients. They were aberrantly expressed in bladder urothelial carcinoma compared to matched histologically normal urothelium (p < 0.001 for each miRNA). CONCLUSIONS/SIGNIFICANCE: To date, this is the first study to determine genome-wide miRNA expression patterns in human bladder urothelial carcinoma by deep sequencing. We found that a collection of miRNAs were aberrantly expressed in bladder urothelial carcinoma compared to matched histologically normal urothelium, suggesting that they might play roles as oncogenes or tumor suppressors in the development and/or progression of this cancer. Our data provide novel insights into cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.